Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/42970Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | VAN DEN BERGH, Joop | - |
| dc.contributor.author | Appelman-Dijkstra, N. M. | - |
| dc.contributor.author | GEUSENS, Piet | - |
| dc.contributor.author | van den Broek, H. J. G. | - |
| dc.contributor.author | Elders, P. J. M. | - |
| dc.contributor.author | de Klerk, G. | - |
| dc.contributor.author | van Oostwaard, M. | - |
| dc.contributor.author | Willems, H. C. | - |
| dc.contributor.author | Zillikens, M. C. | - |
| dc.contributor.author | Lems, W. F. | - |
| dc.date.accessioned | 2024-05-15T14:06:52Z | - |
| dc.date.available | 2024-05-15T14:06:52Z | - |
| dc.date.issued | 2024 | - |
| dc.date.submitted | 2024-05-15T09:17:02Z | - |
| dc.identifier.citation | Archives of Osteoporosis, 19 (1) (Art N° 23) | - |
| dc.identifier.uri | http://hdl.handle.net/1942/42970 | - |
| dc.description.abstract | Background In 2018, a grant was provided for an evidence-based guideline on osteoporosis and fracture prevention based on 10 clinically relevant questions.Methods A multidisciplinary working group was formed with delegates from Dutch scientific and professional societies, including representatives from the patient's organization and the Dutch Institute for Medical Knowledge. The purpose was to obtain a broad consensus among all participating societies to facilitate the implementation of the updated guideline.Results Novel recommendations in our guideline are as follows: - In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA. - Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk; - Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA); - Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk; - A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.Results Novel recommendations in our guideline are as follows: - In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA. - Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk; - Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA); - Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk; - A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.Results Novel recommendations in our guideline are as follows: - In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA. - Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk; - Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA); - Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk; - A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.Results Novel recommendations in our guideline are as follows: - In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA. - Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk; - Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA); - Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk; - A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.Results Novel recommendations in our guideline are as follows: - In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA. - Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk; - Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA); - Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk; - A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.Results Novel recommendations in our guideline are as follows: - In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA. - Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk; - Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA); - Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk; - A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.Conclusion In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 "relatively new statements" that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation. | - |
| dc.language.iso | en | - |
| dc.publisher | SPRINGER LONDON LTD | - |
| dc.rights | The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | - |
| dc.subject.other | Fracture prevention | - |
| dc.subject.other | Multidisciplinary guideline | - |
| dc.subject.other | Osteoporosis | - |
| dc.title | The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena | - |
| dc.type | Journal Contribution | - |
| dc.identifier.issue | 1 | - |
| dc.identifier.volume | 19 | - |
| local.format.pages | 13 | - |
| local.bibliographicCitation.jcat | A1 | - |
| dc.description.notes | van den Bergh, JP (corresponding author), VieCuri Med Ctr, Dept Internal Med, Venlo, Netherlands.; van den Bergh, JP (corresponding author), Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands. | - |
| dc.description.notes | joop.vandenbergh@maastrichtuniversity.nl | - |
| local.publisher.place | 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND | - |
| local.type.refereed | Refereed | - |
| local.type.specified | Article | - |
| local.bibliographicCitation.artnr | 23 | - |
| dc.identifier.doi | 10.1007/s11657-024-01378-3 | - |
| dc.identifier.pmid | 38564062 | - |
| dc.identifier.isi | 001197003500001 | - |
| local.provider.type | wosris | - |
| local.description.affiliation | [van den Bergh, J. P.; van Oostwaard, M.] VieCuri Med Ctr, Dept Internal Med, Venlo, Netherlands. | - |
| local.description.affiliation | [van den Bergh, J. P.; van Oostwaard, M.] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands. | - |
| local.description.affiliation | [Geusens, P.] Maastricht Univ, Med Ctr, Dept Internal Med, Subdiv Rheumatol, Maastricht, Netherlands. | - |
| local.description.affiliation | [Geusens, P.] Hasselt Univ, Dept Med & Life Sci, Hasselt, Belgium. | - |
| local.description.affiliation | [Appelman-Dijkstra, N. M.] Leiden Univ, Med Ctr, Dept Internal Med, Div Endocrinol, Leiden, Netherlands. | - |
| local.description.affiliation | [van den Broek, H. J. G.] Osteoporose Vereniging, Bilthoven, Netherlands. | - |
| local.description.affiliation | [Elders, P. J. M.] Amsterdam UMC, Amsterdam Publ Hlth Inst, Dept Gen Practice, Amsterdam, Netherlands. | - |
| local.description.affiliation | [de Klerk, G.] ADRZ, Dept Surg, Goes, Netherlands. | - |
| local.description.affiliation | [Willems, H. C.] Amsterdam Univ Med Ctr, Dept Internal Med & Geriatr, Amsterdam, Netherlands. | - |
| local.description.affiliation | [Zillikens, M. C.] Erasmus MC, Univ Med Ctr, Dept Internal Med, Rotterdam, Netherlands. | - |
| local.description.affiliation | [Lems, W. F.] Amsterdam Univ Med Ctr, Dept Rheumatol, Amsterdam, Netherlands. | - |
| local.uhasselt.international | yes | - |
| item.contributor | VAN DEN BERGH, Joop | - |
| item.contributor | Appelman-Dijkstra, N. M. | - |
| item.contributor | GEUSENS, Piet | - |
| item.contributor | van den Broek, H. J. G. | - |
| item.contributor | Elders, P. J. M. | - |
| item.contributor | de Klerk, G. | - |
| item.contributor | van Oostwaard, M. | - |
| item.contributor | Willems, H. C. | - |
| item.contributor | Zillikens, M. C. | - |
| item.contributor | Lems, W. F. | - |
| item.fullcitation | VAN DEN BERGH, Joop; Appelman-Dijkstra, N. M.; GEUSENS, Piet; van den Broek, H. J. G.; Elders, P. J. M.; de Klerk, G.; van Oostwaard, M.; Willems, H. C.; Zillikens, M. C. & Lems, W. F. (2024) The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena. In: Archives of Osteoporosis, 19 (1) (Art N° 23). | - |
| item.accessRights | Open Access | - |
| item.fulltext | With Fulltext | - |
| crisitem.journal.issn | 1862-3522 | - |
| crisitem.journal.eissn | 1862-3514 | - |
| Appears in Collections: | Research publications | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena.pdf | Published version | 1.34 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.